C & M PHARMACAL, INC. – Trademark Portfolio

Entity Type: 03

C & M PHARMACAL, INC. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 6 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include GLYTONE. The owner is based in HAZEL PARK, MI.

1519 E. EIGHT MILE RD.

HAZEL PARK, MI 48030

10 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

C & M PHARMACAL, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

3
Cosmetics & Cleaning (6 filings)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does C & M PHARMACAL, INC. have?

C & M PHARMACAL, INC. has 10 U.S. trademarks filed with the USPTO. Of these, 2 registered, 6 abandoned, 2 cancelled.

What trademark classes does C & M PHARMACAL, INC. file in?

C & M PHARMACAL, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.

What are C & M PHARMACAL, INC.'s most well-known trademarks?

C & M PHARMACAL, INC.'s registered trademark portfolio includes well-known marks such as GLYTONE. These are among 2 currently registered trademarks in the portfolio.

What is C & M PHARMACAL, INC.'s trademark registration success rate?

C & M PHARMACAL, INC. has a 20% trademark registration rate, with 2 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.